Keros Therapeutics (KROS) News Today $11.41 +0.55 (+5.06%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cantor Fitzgerald Downgrades Keros Therapeutics (KROS)January 22 at 1:18 AM | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSJanuary 21 at 6:15 PM | prnewswire.comKeros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJanuary 21 at 3:17 PM | markets.businessinsider.comKeros spikes as Teva deal takes effect; Cantor downgrades on trial setbackJanuary 21 at 3:17 PM | msn.comKeros stock climbs on Takeda deal effectivenessJanuary 21 at 10:16 AM | in.investing.comKeros Therapeutics stock rating cut to Neutral, cites dosing setbackJanuary 21 at 10:16 AM | msn.comKeros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to NeutralCantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday.January 21 at 8:19 AM | marketbeat.comKeros Therapeutics' (KROS) "Neutral" Rating Reiterated at GuggenheimJanuary 20 at 2:12 AM | americanbankingnews.comWedbush Downgrades Keros Therapeutics (KROS)January 18, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Price Target Lowered to $41.00 at ScotiabankJanuary 18, 2025 | americanbankingnews.comKeros Therapeutics Downgraded to ‘Hold’ Amid Strategic Shifts and Program RemovalJanuary 17, 2025 | markets.businessinsider.comKeros Therapeutics price target lowered to $15 from $40 at Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler cuts Keros stock target to $15, keeps OverweightJanuary 17, 2025 | msn.comKeros Therapeutics (KROS) Gets a Buy from Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00Piper Sandler dropped their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday.January 17, 2025 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by WedbushWedbush downgraded shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and set a $15.00 price objective for the company. in a research note on Friday.January 17, 2025 | marketbeat.comGuggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS)Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday.January 17, 2025 | marketbeat.comScotiabank Remains a Buy on Keros Therapeutics (KROS)January 17, 2025 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Buy from OppenheimerJanuary 17, 2025 | markets.businessinsider.comScotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock PriceScotiabank dropped their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research report on Thursday.January 16, 2025 | marketbeat.comOppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday.January 16, 2025 | marketbeat.comKeros stock price target cut on study terminationJanuary 16, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Sets New 52-Week Low - What's Next?Keros Therapeutics (NASDAQ:KROS) Sets New 52-Week Low - Here's What HappenedJanuary 16, 2025 | marketbeat.comKeros Therapeutics: Buy Rating Affirmed Despite Setbacks, Driven by Strong Pipeline and Strategic PartnershipsJanuary 16, 2025 | markets.businessinsider.comKeros Therapeutics price target lowered to $32 from $33 at BofAJanuary 16, 2025 | markets.businessinsider.comKeros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse EffectsJanuary 15, 2025 | marketwatch.comKeros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment TrialsJanuary 15, 2025 | marketwatch.comKeros Therapeutics stock falls after trial haltJanuary 15, 2025 | in.investing.comKeros Therapeutics Halts All Dosing In Phase 2 TROPOS Trial For PAH Due To Safety ConcernsJanuary 15, 2025 | markets.businessinsider.comKeros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz SpikesJanuary 15, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Shares Down 8.9% - What's Next?Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9% - Here's WhyJanuary 15, 2025 | marketbeat.comKeros halts hypertension treatment trial on safety issuesJanuary 15, 2025 | reuters.comKeros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialJanuary 15, 2025 | globenewswire.comKeros Therapeutics (NASDAQ:KROS) Trading Down 8.9% - Here's What HappenedKeros Therapeutics (NASDAQ:KROS) Shares Down 8.9% - Here's What HappenedJanuary 13, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and ten have given a buy recommendaJanuary 12, 2025 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low - Here's WhyKeros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low - What's Next?January 8, 2025 | marketbeat.comBank of America Securities Sticks to Its Buy Rating for Keros Therapeutics (KROS)January 6, 2025 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Hits New 1-Year Low - Here's What HappenedKeros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low - Here's What HappenedDecember 30, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. ...December 28, 2024 | gurufocus.comKeros Therapeutics (NASDAQ:KROS) Shares Down 2.7% Following Analyst DowngradeKeros Therapeutics (NASDAQ:KROS) Trading Down 2.7% on Analyst DowngradeDecember 24, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC increased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 6.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 725,621 sharesDecember 24, 2024 | marketbeat.comBarclays PLC Has $3.48 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Barclays PLC boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 140.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 60,014 shares of the company's stock after buying an additional 35,022 shares during the period.December 24, 2024 | marketbeat.comAnalyst’s Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market PotentialDecember 23, 2024 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Price Target Cut to $43.00 by Analysts at Truist FinancialTruist Financial cut their target price on Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a research note on Monday.December 23, 2024 | marketbeat.comFranklin Resources Inc. Trims Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Franklin Resources Inc. lowered its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 28.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,234 shares of the company's stock after sDecember 21, 2024 | marketbeat.comY Intercept Hong Kong Ltd Has $215,000 Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Y Intercept Hong Kong Ltd decreased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 90.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,694 shares of the company's stock after sellinDecember 19, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street CorpState Street Corp cut its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 8.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,113,590 shares of the company's stock after selling 107,786 shares duringDecember 19, 2024 | marketbeat.comKeros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per ShareDecember 18, 2024 | seekingalpha.comKeros Therapeutics: Hold Through The DustDecember 18, 2024 | seekingalpha.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Moderate Buy" from BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and ten haveDecember 18, 2024 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼-0.090.64▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼385▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akero Therapeutics News Belite Bio News Disc Medicine News Amphastar Pharmaceuticals News Wave Life Sciences News Apogee Therapeutics News Indivior News Galapagos News Structure Therapeutics News Arcutis Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts